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The Lancet Asthma Commission highlighted that non-adherence remains a persistent barrier 
within asthma care. Medical consultations remain pivotal in addressing non-adherence, but 
interest in additional adherence support from pharmacists is increasing. This systematic review 
and meta-analysis aims to evaluate how effective pharmacist-led interventions are in improving 
medication adherence in adults with asthma.  
Studies were included if they had adult participants with asthma, pharmacist-led or 
collaborative care interventions, randomised controlled trial (RCT) designs comparing 
interventions with usual pharmacist care, and a medication adherence outcome. We analysed 
adherence data using the standardised mean difference (d) and the remaining data was 
synthesized narratively.  
From 1159 records, 11 were included in the narrative synthesis and nine in the meta-analysis. 
The meta-analysis for adherence produced a medium effect size of d = 0.49 (SE = 0.08, 95% 
CI 0.35-0.64, p < 0.0001) with low statistical heterogeneity.  
In line with the Perceptions and Practicalities Approach (PAPA), interventions targeted to 
address both the perceptions and practicalities that influence individual motivation and ability 
to adhere were more effective. Contextual factors (country and healthcare setting) were also 
influential. Our findings suggest that with adequate remuneration and integration into asthma 
care, pharmacists can help improve adherence in asthma. 
Plain Language Summary 
Many people with asthma get a preventer inhaler to take every day. This inhaler has a small 
dose of steroids that protects the lungs from asthma attacks. These inhalers only protect against 
attacks if they are used every day (as prescribed). Taking medication exactly as prescribed by 
a healthcare professional is known as medication adherence. Forgetting or skipping the inhaler, 
changing the daily dose, or not picking up prescriptions are all examples of medication non-
adherence. Medication non-adherence is common in people with asthma. Pharmacists may 
have the right training and knowledge to help people with asthma take their inhaler more 
consistently. We reviewed past research on this topic by summarising and comparing published 






There are over 300 million people with asthma worldwide and this figure is set to increase by 
100 million by 2025 [1, 2]. Research has consistently demonstrated a link between asthma, 
poor health outcomes, and substantial healthcare costs [3-6]. Better implementation of current 
diagnosis and management strategies may help reduce the impact of asthma globally. However, 
global asthma mortality rates have not changed in over a decade and novel approaches to 
support people with asthma should also be considered [3, 7]. 
Adherence to inhaled preventive asthma medication is sub-optimal in over 50% of people with 
asthma, with the recent Lancet Asthma Commission calling for more effective methods of 
identifying and addressing non-adherence [7, 8]. Although the medical consultation is pivotal, 
there is increasing interest in additional support delivered outside the consultation. Due to the 
growing pressure on primary care practitioners, interest in pharmacist-led adherence support 
has grown, as demonstrated by recent healthcare initiatives and government policy [9-12]. 
Although several studies have examined pharmacist-led adherence support, this literature has 
not been reviewed.  
The aims of our systematic review and meta-analysis were to determine 1.) the overall 
effectiveness of pharmacist-led adherence support for adults with asthma 2.) whether the 
content of interventions influenced their effectiveness. In particular, whether or not they 
applied adherence theory and behaviour change strategies, and 3.) whether the context of 
interventions (country and healthcare setting) influenced their effectiveness [13].  
Methods 
We conducted a systematic review and meta-analysis. Our protocol was registered on the 
International Prospective Register of Systematic Reviews (record CRD42016035657, 
http://www.crd.york.ac.uk/PROSPERO) by the Centre for Reviews and Dissemination (CRD). 
The review is reported in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [14].  
Search strategy  
We searched four pharmacy-relevant databases (EMBASE, MEDLINE, Web of Science, and 
CENTRAL). The search began on May 5th 2016, with weekly alerts for new publications until 
the last search on June 15th 2017. Our search strategy used database-specific vocabulary (e.g. 
Medical Subject Headings) and free text expanding from “pharmacist” and “asthma”. As we 
wanted to capture studies even if adherence was not a primary intervention target, “adherence” 
was not included as a search term. Cochrane Collaboration search filters for identifying 
randomised controlled trials (RCTs) were used on MEDLINE (sensitivity-maximising) and 
EMBASE (sensitivity-and-precision maximising) [15, 16].  We included literature published 
in English, Spanish, German, and Dutch (languages spoken by the research team). There were 
no restrictions on publication date.  
Study selection  
EndNote reference manager was used to store records and remove duplicates [17]. Authors of 
studies were contacted if further information was needed for an inclusion decision. One 
investigator (MM) screened all titles and abstracts. Inclusion decisions were cross-checked 
with other research team members (CK, RH, and ST). Two investigators (CK and MM) 
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independently screened full-text articles. All inconsistent inclusion decisions were resolved 
through consensus.  
Inclusion criteria followed the Participant-Intervention-Comparison-Outcome-Study Design 
(PICOS) framework [15]. Participants were adults with asthma and no other respiratory 
conditions, with a prescription for asthma medication. There were no restrictions on how 
asthma was diagnosed. We excluded participants with other respiratory conditions because 
their medication and adherence behaviour may be different to participants with only an asthma 
diagnosis. During our initial searches, we found many studies that included underage (17 years 
and below) and adult participants (18 years and over). Separate group data were often 
unavailable. We therefore included studies if the majority of participants were adults.  
Intervention content could be partially or completely delivered by a pharmacist (i.e. 
pharmacist-led). Collaborative care interventions delivered with other healthcare professionals 
(e.g. nurses) were included only if pharmacists were involved in delivering intervention 
content. We excluded studies where pharmacists only assisted in research activities (e.g. 
recruitment). Studies had to compare pharmacist-led interventions with usual pharmacist care 
in a RCT design. Usual pharmacist care was defined as dispensing and providing basic 
information about asthma and its treatment.   
We included studies with adherence as a primary or secondary outcome. We focused on 
summary estimates, rather than participant-level data. Where studies used multiple measures 
of adherence, the most objective measure was included in the following order: electronic 
adherence monitoring devices (e.g. Doser™, SmartinhalerTM), pharmacy-based data (e.g. 
prescription refill rates), patient self-report measures, and reports from healthcare professionals 
or carers. RCTs were randomised at the participant or cluster level. We focused only on RCTs 
to compare data of a similar methodological standard.  
Data collection 
Authors of included studies were contacted for further information about study design and 
intervention content. Published protocols were consulted where possible. We used the 
Cochrane Collaboration’s tool to assess risk of bias [18]. We extracted data about research 
design, location, healthcare setting, participants, outcome measures, intervention delivery, and 
intervention content (See Supplement 1). One investigator (MM) extracted this data across all 
studies. Another investigator (CK) independently extracted intervention content data and coded 
risk of bias across 25% of included studies for crosschecking.  
We categorised intervention content based on 1.) whether it was informed by a Perceptions and 
Practicalities Approach (PAPA), as recommended by the National Institute for Health and Care 
Excellence (NICE) guidelines for medicines adherence [19, 20] (Figure 1) and 2.) the 
implemented Behaviour Change Techniques (BCTs) as defined by Michie, Richardson [21]. 
According to the PAPA, tailored interventions targeted to address the perceptions (e.g. beliefs 
about illness and treatment) and practicalities (e.g. capability and resources) affecting 
motivation and ability to adhere to treatment are more effective [19].  
Interventions were categorised as non-PAPA (targeting only perceptions or practicalities), 
partial PAPA (targeting perceptions and practicalities), or full PAPA interventions (tailored 
approach targeting perceptions and practicalities). The BCT Taxonomy is a classification that 
outlines standardised techniques that can change behaviour when applied in the right context 
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(e.g. “demonstration of a behaviour” to teach inhaler technique) [21]. It is a useful tool to 
identify exactly which parts of an intervention are effective.  
Data synthesis 
For our narrative synthesis, we compared studies that found an intervention effect (positive 
studies) with those that did not (negative studies). We first identified differences based on risk 
of bias, research design, location, healthcare setting, participants, outcome measures, and 
intervention delivery to see if they affected adherence outcomes. We then compared studies 
based on intervention content to see if specific components of interventions improved 
adherence.  
Where feasible and appropriate, we conducted a meta-analysis using the standardised mean 
difference (d). We chose a random effects model due to the expected heterogeneity of 
participants and interventions. We chose d because we assumed that adherence is a continuous 
construct regardless of how it is measured. Furthermore, data had to be standardised for 
comparison because studies used different adherence measures [15]. Where necessary, we 
adjusted cluster-randomised studies by inflating standard errors (SEs) using an intra-cluster 
correlation coefficient (ICC) of 0.05, based on previous estimates [22, 23]. We assessed 
heterogeneity (Chi-squared test, I2 statistic, forest plots) and publication bias (funnel plots, fail-
safe N). We conducted sensitivity analyses for ICC used (0.01, 0.05, 0.07, or 0.10), risk of bias 
(high risk studies removed), mixed age samples (studies with participants under 18 years 
removed), and meta-analysis model (fixed and random effects).   
Results 
Study characteristics 
A total of 843 studies were retrieved from the databases. We excluded 797 studies based on 
titles and abstracts and 35 studies were excluded based on full-text articles (Figure 2). Primary 
reasons for exclusion were: same participant sample, not asthma patients, not RCT, author non-
response to request for information, no adherence measure, not pharmacist-led, no usual care 
control group, and unpublished studies (Figure 2). We included 11 studies in the narrative 
synthesis [24-34] and nine studies in the meta-analysis [24-27, 29, 31-34]. Authors of eight 
included studies provided further information upon request [24-26, 29, 30, 32-34]. Two authors 
did not respond [27, 31]. One author was unable to provide further details due to intellectual 
property restrictions [28]. 
Five (45%) studies were cluster-randomised by pharmacy [24, 26-28, 32]. The remaining 
studies were randomised at the participant level (Table 1). All studies met the criteria for a 
usual pharmacist care control group. However, three (27%) of these studies were delivered 
through clinical settings (hospitals and federal health clinics) with a possibly better quality of 
usual care [31, 33, 34]. One (9%) study gave control participants an educational asthma booklet 
and another study (9%) provided inhaler technique training [25, 33]. Studies had a follow-up 
period of four [33], six [24, 25, 27, 29, 31, 32, 34], 5.3 [30], nine [28] and 12 months [26]. 
Studies were conducted in Australia [24], Canada [25], Malta [26], Spain [27], Italy [28], 
Belgium [29], Taiwan [31], Malaysia [32], Brazil [33], and the United States of America (USA) 
[30, 34]. Most interventions (64%) were delivered in community pharmacies. Two (18%) 
interventions were delivered in outpatient clinics [31, 33]. One (9%) intervention was delivered 
completely over the telephone [34]. 
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Five (45%) studies reported on adherence as a primary outcome [26, 31-34]. The most common 
outcome reported was asthma control (73% of studies) [24-29, 32, 34]. Adherence was most 
commonly measured using validated self-report measures (55%) [24, 27, 31-34], followed by 
non-validated self-report measures (36%) [26, 28-30], and prescription refill data (27%) [25, 
29, 33] (Table 1).   
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Armour et al. (2007) [24] Cluster 165 186 6 Australia Community Brief Medication Questionnaire (BMQ) Yes  
Charrois et al. (2006) [25] Patient 36 34 6 Canada Community Prescription refill rates No  
Cordina et al. (2001) [26] Cluster 64 55 12 Malta Community Self-reported rates of forgetting per day No  
García-Cárdenas et al.(2013) [27] Cluster 186 150 6 Spain Community MMAS-4 Yes  
Manfrin et al. (2017) [28] Cluster 400 416 9 Italy Community 2 items from MMAS-8 Yes  
Mehuys et al. (2008) [29] Patient 80 70 6 Belgium Community Prescription refill and Self-report: “How often 
do you not take your controller as prescribed?” 
Yes  
Munzenberger & Hill (2007) [30] Patient 31 29 5.3 USA Community Self-report, appropriate use of inhaled steroid: 
“How often do you take your controller 
medication?”  
No  
Wang et al. (2010) [31] Patient 29 32 6 Taiwan Outpatient MMAS-4 No  
Wong et al. (2017) [32] Cluster 80 77 6 Malaysia Outpatient and 
Telepharmacy 
MALMAS  Yes  
Xaubet Olivera et al. (2016) [33] Patient 52 53 4 Brazil Outpatient MMAS-4 and prescription refill rates  Yes  
Young et al. (2012) [34] Patient 41 42 6 USA Telepharmacy MMAS-8 No  
 
#Community pharmacy (community), ambulatory care/outpatient clinics (outpatient), telephone-based (telepharmacy) 
¶Morisky Medication Adherence Scale (MMAS, 4 and 8 items), Malaysian Medication Adherence Scale (MALMAS) 
+Yes (significant intervention effect, p < 0.05) and No (no significant intervention effect, p ≥ 0.05) 
 




SEX (MALE) UPTAKE ATTRITION ASTHMA 
CONTROL# 
Armour et al. (2007) [24] 50.2 ± 16.4 35.0% - 11.4% Mixed 
Charrois et al. (2006) [25] 37.2 ± 10.5 47.2% 77.4% 1.4% Uncontrolled only 
Cordina et al. (2001) [26] 43.2 ± 18.3 50.6% - 21.7% Mixed 
García-Cárdenas et al.(2013) [27] 55.8 ± 19.1 46.1% 97.1% 9.9% Mixed 
Manfrin et al. (2017) [28] 54.1 ± 17.2 41.2% - 35.4% Mixed 
Mehuys et al. (2008) [29] 35.7 ± 5.5 46.9% 72.8% 25.4% Mixed 
Munzenberger & Hill (2007) [30] 36.1 ± 14.5 23.3% 100% 26.8% Uncontrolled only 
Wang et al. (2010) [31] 28.2 ± 10.9 72.1% - 11.6% Mixed 
Wong et al. (2017) [32] 55.2 ± 13.3 46.5% 79.5% 8.2% Mixed 
Xaubet Olivera et al. (2016) [33] 52.0 ± 10.2 27.6% - 11.8% Mixed 
Young et al. (2012) [34] 44.6 ± 15.8 23.5% 77.8% 15.3% Mixed 
Overall 50.2±16.0 41.8 ± 14.2% 84.1 ± 11.5% 16.3 ± 9.9% -  
 




The mean ± standard deviation (SD) age across the review was 50.2±16.0 years (Table 2). Four 
(36%) studies included a small number of participants under the age of 18; the maximum 
percentage of participants in any one study under 18 years was 23% [25, 26, 29, 30]. The 
mean±SD percentage of male participants was 41.8±14.2%. The median sample size across 
studies was 119, with an interquartile range (IQR) of 170. The median sample size was 64 
(IQR= 84) for the intervention groups and 55 (IQR = 75.5) for the control groups. The 
mean±SD rate of study uptake (percentage of study invitations accepted per invitations 
extended) was high (84.1±11.5%) for the six studies that reported this data [25, 27, 29, 30, 32, 
34]. The mean±SD percentage of participants lost to follow-up was 16.3 ± 9.9%.  
Four (36%) studies had equal proportions of uncontrolled, controlled, and partly controlled 
asthma in their samples [26, 31, 32, 34]. Three (27%) studies had samples with a higher 
proportion of uncontrolled asthma [24, 27, 33]. Two (18%) studies had a higher proportion of 
controlled and partly controlled asthma in their samples [28, 29]. Two (18%) studies focused 
only on uncontrolled asthma [25, 30].  
Risk of bias 
Studies were categorised as having a low [32, 33], moderate [24, 27, 29, 34], or high risk of 
bias [25, 26, 28, 30, 31] (see Supplement 2). The overall risk of bias across the review was 
moderate to high. There was a high risk of performance bias in all studies partly because it is 
difficult to blind participants in behavioural intervention trials as the intervention and control 
conditions are noticeably different. Consequently, eight (73%) studies were judged as having 
a high risk of detection bias because they relied on self-report measures of adherence with non-
blinded participants [24, 26-28, 30-32, 34]. Other sources of bias included possible 
contamination between groups and use of non-validated measures of adherence [25, 26, 28-30, 
34]. 
Effects on medication adherence 
Six (55%) studies found a significant intervention effect on medication adherence (positive 
studies) [24, 27-29, 32, 33]. We adjusted estimates from three studies for clustering [24, 26, 
27]. The random effects meta-analysis produced a medium effect size of d = 0.49 (SE = 0.08, 
95% CI 0.35-0.64, p < 0.0001) [35]. There was low statistical heterogeneity in the analysis 
according to the Chi-squared statistic (χ2 = 9.84, df = 8, p = 0.28), I2 statistic (16.42%), and 
forest plot (Figure 3). Due to the small number of studies in the meta-analysis, we were unable 
to conduct moderator and publication bias analyses. Results remained consistent across all 
sensitivity analyses.  
Intervention delivery  
With regards to intervention delivery, pharmacists were trained using self-study manuals 
and/or interactive workshops. Teaching methods included roleplay and feedback, patient 
actors, group discussions, and question-and-answer sessions [24-26, 28, 30, 34]. Training was 
led by communication reviewers [25, 34], researchers [24, 26, 30], and previously trained 
pharmacists [28]. Nine (81%) interventions were delivered exclusively by pharmacists. Two 
(18%) interventions were delivered by pharmacists in collaboration with nurses [31], or 
respiratory therapists and physicians [25]. One (9%) intervention was delivered over the 
telephone in individual sessions [34]. Another intervention was delivered face-to-face in group 
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sessions with other asthma patients [33] . The remaining interventions (81%) were delivered 
face-to-face in individual sessions.  
Intervention content 
Five (45%) studies were categorised as non-PAPA interventions because they focused solely 
on increasing people’s knowledge about asthma through education, rather than addressing 
people’s perceptions of asthma and/or asthma treatment [25, 26, 29-31]. Although limited 
knowledge of a chronic condition can lead to poor health outcomes, an educational approach 
only addresses the practicalities affecting adherence (i.e. knowledge) [36]. Research shows that 
increased knowledge does not necessarily guarantee behaviour change [37, 38]. One (9%) 
study was categorised as a partial PAPA intervention because it targeted perceptions (e.g. 
beliefs about asthma and its treatment) as well as practicalities (e.g. inhaler technique). 
However, it was delivered in a group setting and this limited the pharmacist’s ability to tailor 
adherence support [33]. The remaining five (45%) studies were categorised as full PAPA 
interventions because they targeted perceptions and practicalities in a tailored manner [24, 27, 
28, 32, 34]. In terms of how interventions tried to change adherence, we coded BCTs across 
eight categories; goals and planning, feedback and monitoring, shaping knowledge, 
comparison of behaviour, repetition and substitution, natural consequences, self-belief, and 
associations (see Supplement 3).   
Discussion 
Main findings 
This is the first systematic review and meta-analysis of pharmacist-led adherence support in 
adults with asthma. Our findings show that pharmacist-led interventions can significantly 
improve medication adherence (medium effect size in meta-analysis, d = 0.49) [35]. In line 
with the NICE guidelines, pharmacist-led interventions applying a full PAPA were more 
effective [19, 20]. The type and number of BCTs used in the intervention did not determine 
effectiveness, though this finding may be due to insufficient data to accurately code BCTs.  
Intervention context (country and healthcare setting) may have influenced effectiveness. 
Interventions delivered in Australia, Belgium, Spain, and Italy may have benefited from 
pharmacist involvement in public health policy [39], adequate pharmacist training and 
remuneration [28, 39-41], and/or more pharmacists per 100,000 people [42]. In contrast, the 
healthcare systems in Canada, Malta, and the USA posed barriers such as fewer pharmacists 
per 100,000 people [43], asthma only being treated in secondary care [26], and limited private 
health insurance coverage beyond medication dispensing [44].  
Our findings are in line with a recent Cochrane review of interventions targeting adherence to 
inhaled corticosteroids (ICS). The review found a significant intervention effect on adherence 
when compared to usual care [45]. In terms of intervention location, previous research looking 
at pharmaceutical care activities and resources across Europe also found significant differences 
between countries [46].  
Limitations of included studies 
None of the studies were able to blind their participants to allocation and this may have 
significantly affected study outcomes [47]. Studies that used self-report measures of adherence 
with non-blinded participants were subject to detection bias. Self-report measures of adherence 
are limited when participants are untruthful [48]. Furthermore, participant behaviour in 
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behavioural intervention trials can be affected by the act of filling in a questionnaire [49]. 
Research suggests that prescription refill data is a more reliable proxy measure of adherence  
[50]. However, it is based on the assumption that medication is taken correctly. This is 
problematic when it comes to asthma medication, where patients may be losing a proportion 
of each dose due to poor inhaler technique [51].  
Contamination between the intervention and control groups may have been an issue in the 
studies randomised at the participant level. Few included studies examined intervention 
fidelity, with only two studies reporting measures to ensure the intervention was being 
delivered as intended [24, 27]. Most studies had a follow-up period of six months, making it 
difficult to assess the sustainability of intervention effects.   
Strengths and limitations of the current review 
This review considered intervention content, delivery, and context when reviewing 
intervention effectiveness, as per current research guidance [52]. We analysed intervention 
content using both the PAPA and the BCT Taxonomy [19, 21] This two-tiered analysis 
approach encompasses both outcome and process, as recommended in the Medical Research 
Council (MRC) guidance for developing and evaluating complex interventions [52]. With 
regards to delivery, we looked at pharmacist training, delivery channels (pharmacist-led or 
collaborative care), and delivery modes (e.g. face-to-face individual sessions). In terms of 
context, we went beyond looking at study location (country) and explored national healthcare 
policies, pharmacy guidelines, and pharmacy literature to explain the differences seen in 
intervention effectiveness.  
The review is limited by the small number of included studies, suggesting a need for further 
research in this area. The generalizability of our findings is limited because we were unable to 
conduct moderator and publication bias analyses. The reliability of our findings is limited by 
the moderate to high risk of bias across the review. However, behavioural intervention trials 
often cannot meet the criteria in the Cochrane Collaboration’s risk of bias tool because it was 
developed based on clinical RCTs [18].  
We did not analyse data for asthma control, the most common primary outcome. However, it 
was felt that a review of data on adherence to asthma medication and subsequent asthma control 
was covered in a recent Cochrane review, so we did not duplicate this [45]. The guidelines for 
a small, medium, and large effect size (d) do not translate directly into the healthcare realm. A 
small effect size for one condition may have a larger clinical impact than a large effect size for 
another condition [53].  
Implications for clinical practice and future research 
In clinical practice, pharmacists can act as “medication experts” providing updated information 
and ongoing support for people with long-term conditions. Community pharmacy interventions 
such as the New Medicine Service (NMS) can significantly increase adherence [54]. These 
interventions offer convenient access points to the healthcare system and ensure consistent 
contact with people through the provision of ongoing pharmaceutical care.  
Our findings suggest that pharmacist-led interventions may be more effective if they are 
integrated into government policy and existing healthcare services. Notably, NHS England 
recently extended the Clinical Pharmacists in General Practice pilot [10]. These embedded 
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pharmacists are working to improve patient safety and quality of care, whilst reducing the 
pressure on General Practitioners (GPs).  
Further RCTs investigating the effect of pharmacist-led interventions on adherence in asthma 
are needed. However, this review has provided an important summary of evidence to date 
highlighting the potential of pharmacist-led interventions. Future studies should aim to reduce 
the risk of detection bias and contamination between groups. Electronic monitoring devices 
should be used to measure adherence, although objective data (e.g. prescription refill rates) 
combined with blinded outcome assessors may be more pragmatic for pharmacy-based 
research. Adequately powered cluster-randomised trials will help reduce the risk of 
contamination between groups.  
To build a reliable evidence base for effective interventions, future publications should report 
intervention content in sufficient detail. This may involve publishing an intervention protocol 
separately. Intervention fidelity measures are needed to ensure that interventions are being 
delivered as reported. Most included studies were conducted in Western cultures [24-30, 34] 
and the cross-cultural applicability of our findings should be explored. Investigating the clinical 
relevance of effect estimates (e.g. d) will help frame the real-life impact of research findings 
for people with asthma.  
As outlined by the Lancet Asthma Commission, monitoring adherence in asthma will be an 
iterative and adaptive process requiring multi-disciplinary input [7]. This review, combined 
with existing evidence, suggests that pharmacist-led interventions can effectively contribute to 
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Supplement 1: Data Extracted from Included Studies 
 
DATA EXTRACTED FROM INCLUDED STUDIES 
CHARACTERISTICS INFORMATION EXTRACTED 
Risk of Bias (Cochrane tool) [18] 
Research Design Study design 
 Unit of randomisation (participant or cluster) 
 Number of intervention and control groups/clusters 
 Nature of control group 
 Length of follow-up (months) 
Context Study location (country) 
 Healthcare setting (e.g. community pharmacy) 
Participants Age (years) 
 Sex (% male participants)  
 Sample size (n - total, intervention group, control group) 
 Study uptake (% invitations accepted) 
 Attrition rate (% baseline sample lost) 
 Baseline differences between intervention and control group 
 Asthma control (controlled, partly controlled, uncontrolled) 
Outcome measures Adherence as primary outcome measure (yes/no) 
 Adherence measures used 
 Other study outcomes  
Intervention delivery Pharmacist training and support 
 Delivery channel (pharmacist versus collaborative care) 
 Delivery mode (e.g. face-to-face individual sessions) 
Intervention content Perceptions and Practicalities Approach (PAPA) [19] 
 Behaviour Change Techniques (BCTs) Taxonomy [21] 
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Supplement 3: Examples of Behaviour Change Techniques (BCTs) Coded Across Studies 
 
EXAMPLES OF BEHAVIOUR CHANGE TECHNIQUES (BCTs) CODED ACROSS STUDIES 
BEHAVIOUR CHANGE 
TECHNIQUE 
CODED IN DEFINITION [21] AND EXAMPLE QUOTE 
1.1 Goal setting (behaviour) Armour et al (2007) [24] Set or agree a goal defined in terms of the behaviour to be achieved 
 
“Eighty-seven (53%) of the intervention patients set goals related to medications (e.g. “remembering to take medications even when well”)… (p.500)” [24]  
1.3 Goal setting (outcome) Armour et al (2007) [24] 
García-Cárdenas et al. (2013) [27] 
Set or agree on a goal defined in terms of a positive outcome of wanted behaviour  
 
“Exercise tolerance (e.g. “increase exercise” and “be more active”) was another common theme of goals…as was asthma control (e.g. “not to wake up at night with 
asthma”)… (p. 500)” [24] 
1.4 Action planning Armour et al (2007) [24] 
Charrois et al. (2006) [25] 
Munzenberger & Hill (2007) [30] 
Wong et al. (2007) [32] 
Young et al. (2012) [34] 
Prompt detailed planning of performance of the behaviour (must include at least one of context, frequency, duration and intensity). Context may be 
environmental (physical or social) or internal (physical, emotional, or cognitive) – includes implementation intentions. 
 
“If necessary, patients received an updated written action plan summarising their medical treatment. (p.149)” [30] 
1.5 Review behaviour goals 
1.7 Review outcome goals 
Armour et al (2007) [24] Review behaviour goal(s)/outcome goal(s) jointly with the person and consider modifying goal(s) or behaviour change strategy in light of achievement.  
 
From published protocol : “Whether or not the patient needed to attend visit 3 was based on the patients’ asthma management and achievement of goals. This decision 
was left to the pharmacists’ discretion. (p.34)” [55] 
2.2 Feedback on behaviour Cordina et al. (2001) [26] 
Manfrin et al. (2017) [28] 
 
Monitor and provide informative or evaluative feedback on performance of the behaviour (e.g. form, frequency, duration, intensity). 
 
“The pharmacists were trained to identify pharmaceutical care issues (PCIs) which could impact on optimal medicines use or asthma control and provide advice to 
patients and recommendations to their GP, as necessary. (p.3)” [28] 
2.4 Self-monitoring of 
outcome of behaviour 
Cordina et al. (2001) [26] 
Wang et al. (2010) [31] 
Establish a method for the person to monitor and record the outcome(s) of their behaviour as part of a behaviour change strategy.  
 
“Patients were monitored by supplying them with a peak flow meter and asking them to record their PEF rate in the morning and evening, together with asthma 
symptoms, on a diary card. Patients were instructed to present their diary card to their community pharmacist for review monthly when patients collected their drugs. 
(p.1198)” [26] 
2.7 Feedback on outcome(s) of 
behaviour 
Cordina et al. (2001) [26] 
Mehuys et al. (2008) [29] 
 
Monitor and provide feedback on the outcome of performance of the behaviour 
 
“Pharmacists [gave] advice based on the [Asthma Control Test] score of the patient…(p. 791)” [29] 
4.1 Instructions on how to 
perform a behaviour 
Armour et al (2007) [24] 
Charrois et al. (2006) [25] 
Cordina et al. (2001) [26] 
García-Cárdenas et al. (2013) [27] 
Mehuys et al. (2008) [29] 
Wong et al. (2007) [32] 
Xaubet Olivera et al. (2016) [33] 
Young et al. (2012) [34] 
 
 
Advise or agree on how to perform the behaviour (includes “Skills Training”) 
 
“Patients were educated using verbal instructions, physical demonstration, and written information about turbuhaler use (p.1348)” [27] 
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4.2 Information about 
antecedents 
García-Cárdenas et al. (2013) [27] 
Xaubet Olivera et al. (2016) [33] 
 
Provide information about antecedents (e.g. social and environmental situations and events, emotions, cognitions) that reliably predict performance of the 
behaviour 
 
“When appropriate, the type of non-adherence (intentional or unintentional) and causes of intentional nonadherence were explored with the Beliefs about Medicines 
Questionnaire and Health Beliefs Model. (p.1348)” [27] 
5.1 Information about health 
consequences 
Armour et al (2007) [24] 
Cordina et al. (2001) [26] 
Wang et al. (2010) [31] 
Wong et al. (2007) [32] 
Provide information (e.g. written, verbal, visual) about health consequences of performing the behaviour 
 
“PharMS consisted of (i) education on asthma (including signs and symptoms, trigger factors, consequences of uncontrolled asthma) with the aid of a booklet which 
was especially designed for asthma patients (p.4)” [32] 
6.1 Demonstration of the 
behaviour 
Armour et al (2007) [24] 
Charrois et al. (2006) [25] 
Cordina et al. (2001) [26] 
García-Cárdenas et al. (2013) [27] 
Wong et al. (2007) [32] 
Provide an observable example of the performance of the behaviour, directly in person or indirectly e.g. via film, pictures, for the person to aspire to or 
imitate 
 
“Verbal education and demonstration of inhaler technique were supported by written information and provision of a short videotape for home viewing. (p.1198)” [26] 
7.5 Remove aversive stimulus Armour et al (2007) [24] 
Charrois et al. (2006) [25] 
Cordina et al. (2001) [26] 
Manfrin et al. (2017) [28] 
Advise or arrange for the removal of an aversive stimulus to facilitate behaviour change  
 




Mehuys et al. (2008) [29] 
 
Prompt practice or rehearsal of the performance of the behaviour one or more times in a context or at a time when the performance may not be necessary, in 
order to increase habit and skill 
 
From protocol (Translated from Flemish): “Next, ask the patient to use their inhaler again and check whether he/she has mastered the correct technique. (p.4)” [56]  
15.1 Verbal persuasion about 
capability 
Young et al. (2012) [34] Tell the person that they can successfully perform the wanted behaviour, arguing against self-doubts and asserting that they can and will succeed 
 
From published protocol: “Pharmacists used motivational interviewing (MI) to address problems related to low self-efficacy or motivation. MI is a theory-based skilful 
clinical method and style of counselling and psychotherapy designed for assessing patients’ source of motivation and assisting patients to commit to change. MI has 
been found to overcome motivational barriers and adhere to prescribed regimens. (p.5)” [57] 
 
